Few things NOT to do when asking for a research rotation/position: 1) Don’t mass email, especially with cc in same email—it is a turnoff when many people cced, or if we forward email to a colleagues to see if they can help & find out same mass email has been sent to many 2) Proof read your email multiple times, & especially if you are not native English speaker, ask someone who is to proof read before you send. Spelling, grammar and especially multiple errors can be a kiss of death for many investigators

At @ASH_hematology #ASH22 highlights I am being told some transplanters are refusing to do #AlloHSCT for otherwise eligible #AMLSm younger pts in CR because of bialleic #TP53 +MRD, I don’t think this is acceptable. Counsel on poor outcomes but there is a tail at end of OS curve

https://twitter.com/BrianShafferMD/status/1614310060452368386

Even if it 10%. I anecdotally had few pts who lived for years post transplant going in with TP53 bialleic complex type & MRD+ CR. I don’t think you should deprive pt only possibly of cure just to try to eradicate pre-allo MRD which often does not occur with any pre-transplant tx

Reflections on Twitter debates regarding clinical trials 1) No one disagrees that the way clinical trials in Oncology are designed/conducted leaves much to be desired with many inefficiencies & problems. However as often is the case, change will only happen from within the system 2) Change is often incremental & an evolution & not a revolution, & it requires active participation from all stakeholders. While industry bears some blame, we should remember their primary responsibility (even if they say otherwise) is to their shareholders & not to patients

Investigator-initiated trials should receive more recognition by academia. The time & effort that go into getting funding, designing, conducting, & maintaining compliance are enormous. Still they get judged based mostly on clinical results & often wind up in low-impact journals. Many reviewers & journals do not seem to manage their expectations or recognize the difference between papers describing a clinical trial conducted and written by an army of industry personnel and medical writers compared to an IIT that was run on limited resources and personnel